Carotid Endarterectomy: Indications and Perioperative Management
Indications for CEA
Carotid endarterectomy is indicated for symptomatic patients (TIA, nondisabling stroke, or amaurosis fugax within 6 months) with >70% stenosis by noninvasive imaging or >50% by catheter angiography, provided the anticipated perioperative stroke/death rate is <6%. 1
Symptomatic Disease
- Perform CEA in average or low surgical risk patients with recent cerebral ischemic symptoms and ipsilateral internal carotid stenosis >70% by duplex/CTA/MRA or >50% by catheter angiography 1
- The anticipated perioperative stroke or mortality must be <6% 1
- Nondisabling stroke refers generally to Modified Rankin Scale <3 1
Asymptomatic Disease
- CEA is reasonable for asymptomatic patients with >70% stenosis if perioperative stroke/MI/death risk is low 1
- Selection requires assessment of comorbidities, life expectancy, and thorough discussion of risks versus benefits 1
Timing of Surgery
For symptomatic patients without contraindications, intervention within 2 weeks of the index event is reasonable rather than delaying surgery. 1
- Urgent CEA (within 24-72 hours) is beneficial in carefully selected neurologically unstable patients with crescendo TIAs or progressing stroke 2, 3
- Despite slightly higher perioperative morbidity, urgent intervention prevents progression to completed stroke in unstable patients 3
- For minor stroke with limited brain infarction, semi-urgent CEA within 2 weeks is preferred over the traditional 6-week waiting period 3
- Emergency treatment within 24 hours shows no additional benefit over intervention within 48 hours 2
Antiplatelet Therapy
Aspirin 81-325 mg daily must be started before CEA and continued indefinitely postoperatively. 1
Preoperative Management
- Low-dose aspirin (81-325 mg daily) should be continued throughout the perioperative period 1
- Higher aspirin doses confer no additional benefit 4
- For aspirin-allergic patients, clopidogrel 75 mg daily or ticlopidine 250 mg twice daily is a reasonable alternative 1
Dual Antiplatelet Therapy (DAPT)
- Avoid DAPT (aspirin plus clopidogrel) during CEA when possible, as it increases bleeding risk (RR 1.6) despite only modestly reducing stroke risk (RR 0.80). 5
- DAPT is NOT recommended within 3 months after stroke or TIA for CEA patients 1
- However, emerging evidence suggests early DAPT in recently symptomatic patients may reduce recurrent cerebral events before CEA and early postoperative carotid thrombosis 4
- If DAPT is used, aggressive post-CEA hypertension management is essential 4
Long-term Prophylaxis
- Beyond the first month after CEA, continue aspirin 75-325 mg daily, clopidogrel 75 mg daily, or aspirin plus extended-release dipyridamole (25/200 mg twice daily) 1
Anticoagulation
- Antiplatelet agents are recommended over oral anticoagulation for extracranial carotid atherosclerosis 1
- Full-intensity parenteral anticoagulation with unfractionated heparin or low-molecular-weight heparin is NOT recommended for patients developing TIA or acute ischemic stroke 1
- For patients requiring anticoagulation (atrial fibrillation, mechanical valve), warfarin with target INR 2.5 (range 2.0-3.0) can be beneficial 1
Statin Therapy
Statins should be started preoperatively to reduce perioperative myocardial infarction and stroke, especially in symptomatic patients. 4
- Initiate statin therapy regardless of baseline lipid levels 6
- Statins reduce recurrent cerebral events before CEA 4
Blood Pressure Management
Maintain mean arterial pressure ≥20% above baseline during carotid cross-clamp to optimize collateral cerebral blood flow and reduce cognitive dysfunction. 7
Intraoperative Management
- MAP ≥20% above baseline during cross-clamp is associated with significantly lower risk of early cognitive dysfunction (OR 0.18) 7
- This strategy optimizes collateral cerebral blood flow and reduces ischemic injury risk 7
Postoperative Management
- Aggressively treat post-CEA hypertension, which is especially common in recently symptomatic patients undergoing surgery within 7-14 days of symptom onset 4
- Untreated post-CEA hypertension is associated with intracerebral hemorrhage, hyperperfusion syndrome, and major cardiac events 4
- Each unit should have written protocols for prompt treatment of post-CEA hypertension 4
Heparin Reversal
Protamine reversal of heparin is increasingly common and reduces neck hematomas without significantly increasing thromboembolic stroke. 4
- Protamine use does not significantly increase perioperative thromboembolic stroke 4
- It reduces the prevalence of neck hematomas, which are associated with increased stroke/death risk after re-exploration 4
Follow-up Imaging
Noninvasive imaging of the extracranial carotid arteries is reasonable at 1 month, 6 months, and annually after CEA to assess patency and exclude new or contralateral lesions. 1
- Once stability is established over an extended period, surveillance intervals may be lengthened 1
- Terminate surveillance when the patient is no longer a candidate for intervention 1, 6
Management of Restenosis
For symptomatic recurrent carotid stenosis due to intimal hyperplasia or atherosclerosis, repeat CEA or CAS is reasonable using the same criteria as initial revascularization. 1
- Reoperative CEA or CAS is reasonable for rapidly progressive restenosis threatening complete occlusion 1
- In asymptomatic patients with recurrent stenosis, reoperative intervention may be considered using initial revascularization criteria 1
- Do NOT perform reoperative CEA or CAS in asymptomatic patients with <70% stenosis that has remained stable 1
Key Contraindications and Pitfalls
- Chronic total occlusion of the target vessel is a contraindication to revascularization 6
- Avoid CEA in patients with severe disability (Modified Rankin Scale ≥3) that limits functional benefit 6
- Limited life expectancy or prohibitive comorbidities preclude meaningful benefit 6
- Withhold antiplatelet therapy for 24 hours after thrombolysis completion 4